• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 6, 2015

View Archived Issues

Pharma: Other news to note

Actavis plc, of Dublin, confirmed that the U.S. District Court for the District of New Jersey found that U.S. Patent Nos. 7,645,459 and 7,645,460 protecting bisphosphonate Atelvia (risedronate sodium delayed-release tablets, 35 mg) in the U.S. are invalid. Read More

In the clinic

Chiasma Inc., of Newton, Mass., said phase III data presented at the Endocrine Society meeting in San Diego, showed baseline responses of acromegaly patients to injectable somatostatin analogues can predict response to Chiasma's octreotide, an oral somatostatin analogue. Read More

Earnings

Alimera Sciences Inc., of Atlanta, said net revenue increased by approximately $760,000, or 81 percent, to $1.7 million for the fourth quarter of 2014, compared to $940,000 in the fourth quarter of 2013. Read More

Other news to note

Biommune Technologies Inc., of Vancouver, British Columbia, demonstrated in vivo that anticancer activity induced by small-molecule drugs can make cancer cells more visible to the immune system. Read More

Stock movers

Read More

Regulatory front

Biosimilar approvals in the U.S. are expected to increase during the next five years, but safety concerns among physicians and the need for greater regulatory clarity concerning therapeutic interchangeability could hinder market uptake, according to a new Tufts Center for the Study of Drug Development (CSDD) study. Read More

Novartis hit with 15-day Japan sales suspension after reporting probe

HONG KONG – Starting March 5, Japan's regulator suspended a subsidiary of Novartis AG from manufacturing or selling drugs, citing a string of unreported negative side effects patients suffered after using the company's drugs. Read More

Eisai, Merck team up for pembrolizumab combo cancer trials

TOKYO – Japan's Eisai Co. Ltd. will work with multinational Merck & Co. Inc. to jointly develop combination cancer regimens. Read More

Kythera shares climb on upbeat adcom briefing

FDA reviewers gave agency advisors the proverbial chin nod in documents briefing them on Kythera Biopharma Inc.'s submental fat reduction drug, ATX-101 (deoxycholic acid), ahead of a March 9 advisory committee meeting, saying company data support a "favorable benefit-risk assessment" of the injectable, an appraisal that boosted Kythera shares (NASDAQ:KYTH) 25.3 percent to $50 on Thursday. Read More

Antidepressants might be the best heart drugs around

Several studies have shown surprising effects of antidepressants in patients with cardiovascular problems. A paper published in the March 5, 2015, issue of Science Translational Medicine indicated that the antidepressant Paxil (paroxetine, Glaxosmithkline plc) was better than beta blockers at treating heart failure after an experimental heart attack in mice. Read More

Arrowhead staking a bigger claim to RNAi space in Novartis deal

The latest foray in the oft-thorny RNAi patent landscape sees Arrowhead Research Corp. nabbing the entire RNAi portfolio of Novartis AG, picking up rights to a host of intellectual property (IP) and assets, including an existing license agreement with RNAi powerhouse Alnylam Pharmaceuticals Inc., a pipeline of three preclinical candidates and a patent estate the Pasadena, Calif.-based biotech said falls safely outside the scope of competitors' IP. Read More

Mallinckrodt takes Ikaria, inpatient drug portfolio for $2.3B

Mallinckrodt plc plans to amp up its hospital-based drug portfolio with the acquisition of privately held Ikaria Inc. in a transaction valued at approximately $2.3 billion. Hampton, N.J.-based Ikaria, which is focused on therapies and delivery systems for critically ill infants in hospital neonatal intensive care unit (NICU) settings, markets Inomax, a continuous flow version of inhaled nitric oxide. Read More

Pharma: In the clinic

Takeda Oncology Inc., of Cambridge, Mass., said the New England Journal of Medicine published phase III data showing that Velcade (bortezomib)-based therapy was found to be more effective than standard of care in previously untreated mantle cell lymphoma patients. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 26, 2025.
  • Deal handshake with coin, chart background

    After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

    BioWorld
    Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc. reported raising $175 million in private...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • !insulet dexcom CGM

    Pump manufacturers: Patches are the fix for low AID uptake

    BioWorld MedTech
    The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with clear health benefits and payer...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe